GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Selling and Marketing Expense

TNF Pharmaceuticals (LTS:0A8D) Selling and Marketing Expense : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. TNF Pharmaceuticals's Selling and Marketing Expense for the three months ended in Mar. 2025 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

TNF Pharmaceuticals Selling and Marketing Expense Historical Data

The historical data trend for TNF Pharmaceuticals's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Selling and Marketing Expense Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Selling and Marketing Expense
- - - - -

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TNF Pharmaceuticals Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TNF Pharmaceuticals Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Selling and Marketing Expense
Comparable Companies
APVO SCNI VCNX AGTX PBM OMGAQ THAR ZVSA QLGN KANT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
TNFA:USA
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Website
https://tnfpharma.com
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines